Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease
- Status
- COMPLETED
- Phase
- PHASE2
PAD. ICORG 05-01, V11
- Status
- COMPLETED
- Phase
- PHASE2
Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE2
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
- Status
- COMPLETED
- Phase
- NA
Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE2
Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
- Status
- COMPLETED
- Phase
- PHASE3
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL
- Status
- TERMINATED
- Phase
- NA
Randomized Trial for Mixed Acute Rejection
- Status
- COMPLETED
- Phase
- PHASE2